Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy

Gene Therapy

Volumn 3, Issue 12, 1996, Pages 1143-1150

  Bailey, S M ^a   Knox, R J ^b   Hobbs, S M ^b   Jenkins, T C ^b   Mauger, A B ^b   Melton, R G ^c   Burke, P J ^d   Connors, T A ^e   Hart, I R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CB1954; Gene therapy; Nitrofurazone; Nitroreductase; Suicide gene

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; BACTERIAL ENZYME; FLUOROURACIL; NITROFURAL; NITROREDUCTASE; PRODRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA TRANSFECTION; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME SUBSTRATE; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CATALYSIS; CELL LINE; CRICETINAE; CRICETULUS; ESCHERICHIA COLI; GENE THERAPY; NEOPLASMS; NITROREDUCTASES; PRODRUGS; TRANSFECTION;

EID: 0030458785     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
2. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Therapy 1995; 2: 702-709.
3. Bridgewater JA et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995; 31A. 2362-2370.
4. Knox RJ, Friedlos F, Boland MP. The bioactivation of CB1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev 1993; 12: 195-212.
5. Boland MP, Knox RJ, Roberts JJ. The differences in kinetics of rat and human DT-diaphorase result in a differential sensitivity of derived cell lines to CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 1991; 41: 867-875.
6. Anlezark GM et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitro7 reductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1992; 44: 2289-2295.
7. Knox RJ et al. Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1995; 49: 1641-1647.
8. Anlezark GM et al. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 1995; 50: 609-618.
9. Mauger AB et al. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjugation with a nitroreductase enzyme. J Med Chem 1994; 37: 3452-3458.
10. Stratford IJ, Stephens HNC. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 1989; 16: 973-976.
11. Knox RJ et al. The bioactivation of 5-(aziridin-l-yl)-2,4-dimtro-benzamide (CB1954). II A comparison of an Escherichia coli nitroreductase and Walker DT-diaphorase. Biochem Pharmacol 1992; 44: 2297-2301.
12. Chen CY et al Effect of herpes simplex virus thymidine kinase levels on ganciclovir-mediatecl cytotoxicity in the 'bystander effect'. Hum Gene Ther 1995; 6: 1467-1476.
13. Workman P, Walton MI. Enzyme-directed bioreductive drug development In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. Plenum Press: New York, 1990, pp 173-191.
14. Bailey SM, Suggett N, Walton MI, Workman P. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones. Int J Radiat Oncol Biol Phys 1992; 22: 649-653
15. Fisher GR, Gutierrez PL, Oldcome MA, Parterson LH. NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase)-mediated two-electron reduction of anthraquinone-based antitumour agents and generation of hydroxyl radicals. Biochem Pharmacol 1992; 43: 575-585.
16. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of diaziquone by NAD(P)H: (quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990; 50: 7293-7300.
17. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990; 50: 7482-7489.
18. Fitzsimmons SA et al. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996; 88: 259-269.
19. Fisher GR, Gutierrez PL. Free radical formation and DNA strand breakage during metabolism of diaziquone by NAD(P)H quinone-acceptor oxidoreductase (DT-diaphorase) and NADPH cytochrome c reductase. Free Radic Biol Med 1991; 11: 597-604.
20. Bailey SM, Lewis AD, Workman P. Involvement of NADPH: cytochrome P450 reductase in activation of EO9 to a DNA damaging species. Br J Cancer 1994; 69: 57.
21. Walton MI, Wolf CR, Workman P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WLN 59075) by mouse liver. Biochem Pharmacol 1992; 44: 251-259.
22. Hartley JA. Selectivity in alkylating agent-DNA interactions. In: Neidle S, Waring M (eds). Molecular Aspects of Anticancer Drug-DNA Reactions. Vol. 1. Macmillan Press: Basingstoke, 1993, pp 1-32.
23. O'Neill P et al Mechanism of action of some bioreducible 2-nitroimidazoles: comparison of in vitro cytotoxicity and ability to induce DNA strand breakage Anti-Cancer Drag Des 1987; 1: 271-280.
24. Jenkins TC et al. Synthesis and evaluation of α[[(2-haloethyl)amino]methyl]-2-nitro-1H-imidazole-1- ethanols as prodrugs of α[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 1990; 33: 2603-2610.
25. Skonieczny S. A review on the synthesis of the 9-substituted acridines. Heterocycles 1977; 6: 987-1060.
26. Thuong NT, Asseline U. Oligonucleotides attached to intercalators, photoreactive and cleavage agents. In: Eckstein F (ed). Oligonucleotides and Analogues. IRL Press: Oxford, 1991, pp 283-306.
27. de la Luna S et al. Efficient transformation of mammalian cells with constructs containing a puromycin-resistance marker. Gene 1988; 62: 121-126.
28. Michael NP, Brehm JK, Anlezark GM, Minton NP. Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its overexpression in Escherichia coli K12. FEMS Microbiol Lett 1994; 124: 195-202.
29. Kozak M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 1984; 12: 857-872.
30. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
31. Knox RJ et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-hydroxylamino-2-nitrobenzamide (CB1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2,4-dinitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2) Biochem Pharmacol 1988; 37: 4671-4677.
32. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.